FrancophonIA/ELRC3.0 huggingface dataset:
English: In these pharmacokinetic trials, the exposure of atazanavir 300 mg with cobicistat 150 mg was consistent with that observed when boosted with ritonavir 100 mg. EVOTAZ is bioequivalent to atazanavir 300 mg once daily in combination with cobicistat 150 mg once daily coadministered as single agents (see section 5.2).
Slovenian: V teh farmakokinetičnih preskušanjih je bila izpostavljenost atazanavirju pri uporabi atazanavirja v odmerku 300 mg skupaj s kobicistatom v odmerku 150 mg konsistentna z izpostavljenostjo pri okrepitvi z ritonavirjem v odmerku 100 mg.
English: Concentrations of these calcium channel blockers may be increased when co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se koncentracije teh zaviralcev kalcijevih kanalčkov lahko povečajo.
English: Efavirenz 600 mg once daily (atazanavir 400 mg once daily)
Slovenian: Efavirenz 600 mg enkrat na dan (atazanavir 400 mg enkrat na dan)
English: Elbasvir 50 mg once daily (atazanavir 300 mg / ritonavir 100 mg once daily
Slovenian: Elbasvir 50 mg enkrat na dan (atazanavir 300 mg/ritonavir 100 mg enkrat na dan)
English: Tenofovir alafenamide 10 mg once daily/emtricitabine 200 mg once daily (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Slovenian: Alafenamidtenofovirat 10 mg enkrat na dan/emtricitabin 200 mg enkrat na dan (atazanavir 300 mg enkrat na dan s kobicistatom 150 mg enkrat na dan)
English: GASTROINTESTINAL MOTILITY AGENTS Cisapride
Slovenian: PROKINETIKI Cisaprid
English: If you miss a dose and it is more than 12 hours from the time you should have taken EVOTAZ, do not take the missed dose.
Slovenian: Če pa je bolnik pozabil vzeti odmerek zdravila EVOTAZ ob običajnem času in je od tega minilo že več kot 12 ur, pozabljenega odmerka ne sme vzeti.
English: Boceprevir 800 mg three times daily (atazanavir 300 mg/ritonavir 100 mg once daily)
Slovenian: Boceprevir 800 mg trikrat na dan (atazanavir 300 mg/ritonavir 100 mg enkrat na dan)
English: The combination of rifampicin and EVOTAZ is contraindicated (see section 4.3).
Slovenian: Uporaba rifampicina v kombinaciji z zdravilom EVOTAZ je kontraindicirana (glejte poglavje 4.3).
English: As EVOTAZ contains atazanavir and cobicistat, any interactions that have been identified with these active substances individually may occur with EVOTAZ.
Slovenian: Zdravilo EVOTAZ vsebuje atazanavir in kobicistat, zato pri uporabi zdravila EVOTAZ lahko pričakujemo pojav vseh interakcij, ki so bile ugotovljene pri uporabi posameznih učinkovin.
English: For these sedatives/hypnotics, dose reduction may be necessary and concentration monitoring is recommended.
Slovenian: Odmerek teh sedativov/hipnotikov bo morda treba zmanjšati.
English: Renal and urinary disorders uncommon nephrolithiasisa, haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney diseasea rare kidney pain
Slovenian: Bolezni sečil občasni nefrolitiazaa, hematurija, proteinurija, polakisurija, intersticijski nefritis, kronična ledvična bolezena redki bolečina v ledvicah
English: Drug interaction trials were not conducted for EVOTAZ.
Slovenian: Preskušanja medsebojnega delovanja med zdravilom EVOTAZ in drugimi zdravili niso bila izvedena.
English: Tell your doctor if you notice anything unusual about your health.
Slovenian: Če opazite karkoli neobičajnega, o tem obvestite zdravnika.
English: Exposure to clarithromycin is expected to increase if co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ pričakujemo povečanje izpostavljenosti klaritromicinu.
English: Clarithromycin Cmin ↑160%
Slovenian: Klaritromicin Cmin ↑160% (↑135%
English: Co-administration of EVOTAZ and these ergot derivates is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba zdravila EVOTAZ in teh derivatov ergot alkaloidov je kontraindicirana (glejte poglavje 4.3).
English: EVOTAZ is not recommended for patients undergoing haemodialysis (see sections 4.4 and 5.2).
Slovenian: Pri bolnikih, ki se zdravijo s hemodializo, uporaba zdravila EVOTAZ ni priporočljiva (glejte poglavji 4.4 in 5.2).
English: Omeprazole 40 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily, 2 hours after omeprazole)
Slovenian: Omeprazol 40 mg enkrat na dan (atazanavir 300 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan, 2 uri po omeprazolu)
English: No dose adjustment of cobicistat is required in patients with mild or moderate hepatic impairment.
Slovenian: Pri bolnikih z blago ali zmerno okvaro jeter odmerka kobicistata ni treba prilagajati.
English: Renal impairment Atazanavir
Slovenian: Okvara jeter Atazanavir
English: gait disturbance (abnormal manner of walking) oedema (swelling), palpitation (fast or irregular heart beat) hepatosplenomegaly (enlargement of the liver and spleen) vesiculobullous rash (visible accumulation of fluid under the skin), eczema (skin rash), vasodilatation (widening of blood vessels)
Slovenian: Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) podaljšanje intervala QTc (nepravilno bitje srca) motnje hoje (nenormalen način hoje) edem (oteklina), palpitacije (hitro ali nepravilno utripanje srca) hepatosplenomegalija (povečanje jeter in vranice) vezikobulozen izpuščaj (vidno nakopičenje tekočine pod kožo), ekcem (kožni izpuščaj), vazodilatacija (razširjenost žil)
English: Rifabutin 150 mg twice weekly (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Slovenian: Rifabutin 150 mg dvakrat na teden (atazanavir 300 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan)
English: Omeprazole 20 mg once daily am (atazanavir 300 mg once daily with ritonavir 100 mg once daily pm, 12 hours after omeprazole)
Slovenian: Omeprazol 20 mg enkrat na dan dopoldan (atazanavir 300 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan popoldan, 12 ur po omeprazolu)
English: Rosuvastatin (10 mg single dose) (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Slovenian: Rosuvastatin (10 mg enkratni odmerek) (atazanavir 300 mg enkrat na dan s kobicistatom 150 mg enkrat na dan)
English: Hyperbilirubinaemia (an increase in the level of bilirubin in the blood) has occurred in patients receiving EVOTAZ.
Slovenian: Pri bolnikih, ki so se zdravili z zdravilom EVOTAZ, so poročali o pojavu hiperbilirubinemije (zvišanje vrednosti bilirubina v krvi).
English: The mechanism of interaction is CYP3A4 and P-gp inhibition by cobicistat.
Slovenian: Mehanizem interakcije je zaviranje CYP3A4 in P-gp s kobicistatom.
English: Based on the very limited renal elimination of cobicistat and atazanavir, no special precautions or dose adjustments of EVOTAZ are required for patients with renal impairment.
Slovenian: Pri bolnikih z okvaro ledvic posebni previdnostni ukrepi niso potrebni in odmerka zdravila EVOTAZ ni treba posebej prilagajati, saj je izločanje kobicistata in atazanavirja preko ledvic zelo omejeno.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 300 mg of atazanavir (as sulphate) and 150 mg of cobicistat.
Slovenian: NAVEDBA ENE ALI VEČ UČINKOVIN Ena filmsko obložena tableta vsebuje 300 mg atazanavirja (v obliki sulfata) in 150 mg kobicistata.
English: The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or cobicistat and clarithromycin.
Slovenian: Mehanizem interakcije je zaviranje CYP3A4 z atazanavirjem in/ali kobicistatom in klaritromicinom.
English: Exposure to diltiazem and a metabolite, desacetyl-diltiazem, is increased when diltiazem is co-administered with atazanavir, a component of EVOTAZ.
Slovenian: Pri sočasni uporabi atazanavirja, sestavine zdravila EVOTAZ, se izpostavljenost diltiazemu in njegovemu presnovku dezacetil-diltiazemu poveča.
English: Respiratory, thoracic and mediastinal disorders uncommon dyspnoea
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora občasni dispneja
English: Concentrations of atazanavir given with cobicistat are expected to be increased in patients with impaired hepatic function (see sections 4.2 and 4.4).
Slovenian: Pri bolnikih z zmerno ali hudo okvaro delovanja jeter lahko pri uporabi atazanavirja skupaj s kobicistatom pričakujemo povečanje koncentracij atazanavirja (glejte poglavji 4.2 in 4.4).
English: In rats, ossification changes in the spinal column and sternebra of foetuses occurred at a dose that produced significant maternal toxicity.
Slovenian: Pri podganah so se pri odmerku, ki je bil pomembno toksičen za matere, pojavile spremembe v zakostenitvi hrbtenice in prsnice plodov.
English: Clinical monitoring of therapeutic effect and adverse events is recommended when these medicinal products are co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi teh zdravil in zdravila EVOTAZ priporočamo nadziranje terapevtskega učinka in neželenih učinkov.
English: Co-administration of EVOTAZ and indinavir is not recommended (see section 4.4).
Slovenian: Sočasna uporaba zdravila EVOTAZ in indinavirja ni priporočljiva (glejte poglavje 4.4).
English: In particular, atazanavir boosted with cobicistat is more sensitive for CYP3A induction (see section 4.3 and the interaction table).
Slovenian: Priporočila za sočasno uporabo atazanavirja in drugih zdravil so torej odvisna od tega, ali je atazanavir okrepljen z ritonavirjem ali s kobicistatom, še posebej, ker je atazanavir, okrepljen s kobicistatom, bolj občutljiv za indukcijo CYP3A (glejte poglavje 4.3 in interakcije, prikazane v tabeli).
English: EVOTAZ is not recommended in patients undergoing haemodialysis (see sections 4.2 and 5.2).
Slovenian: Pri bolnikih, ki se zdravijo s hemodializo, uporaba zdravila EVOTAZ ni priporočljiva (glejte poglavji 4.2 in 5.2).
English: Concentrations of these immunosuppressants may be increased when co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se koncentracije teh imunosupresivov lahko povečajo.
English: Gall stones have been reported in patients taking atazanavir, a component of EVOTAZ.
Slovenian: Pri bolnikih, ki so jemali atazanavir, sestavino zdravila EVOTAZ, so poročali o pojavu žolčnih kamnov.
English: Rifampicin 600 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Slovenian: Rifampicin 600 mg enkrat na dan (atazanavir 300 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan)
English: Subjects with significant liver function test abnormalities generally had abnormal baseline transaminases (AST or ALT), underlying chronic or acute hepatitis B or C co-infection, concomitant hepatotoxic medications (e.g., isoniazid), or a medical history of alcoholism or alcohol abuse.
Slovenian: V študiji GS-US-216-0114 je bilo 3,6 % bolnikov pozitivnih za površinski antigen virusa hepatitisa B in 5,3 % bolnikov seropozitivnih za virus hepatitisa C. Bolniki s pomembnimi nepravilnostmi, ugotovljenimi pri preiskavah delovanja jeter, so na splošno imeli nenormalne izhodiščne vrednosti aminotransferaz (AST ali ALT), kronično ali akutno okužbo z virusom hepatitisa B ali C kot osnovno bolezen, so se sočasno zdravili s hepatotoksičnimi zdravili (npr. izoniazid) ali pa so imeli anamnezo alkoholizma ali zlorabe alkohola.
English: Make sure your doctor knows: if you have liver problems if you develop signs or symptoms of gall stones (pain in your right side).
Slovenian: v primeru pojava znakov ali simptomov žolčnih kamnov (bolečina v desnem predelu telesa).
English: Co-administration of EVOTAZ and cisapride is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba zdravila EVOTAZ in cisaprida je kontraindicirana (glejte poglavje 4.3).
English: Talk to your doctor about breast-feeding if you are taking EVOTAZ.
Slovenian: Zdravnika morate obvestiti: če imate težave z jetri.
English: Clinical monitoring is recommended when dabigatran is co-administered with P-gp inhibitors.
Slovenian: Pri sočasni uporabi dabigatrana in zaviralcev P-gp priporočamo klinični nadzor.
English: Metabolic parameters
Slovenian: Presnovni parametri:
English: ERECTILE DYSFUNCTION
Slovenian: ZDRAVILA ZA ZDRAVLJENJE EREKTILNE DISFUNKCIJE
English: Concentrations of dabigatran may be affected upon co-administration with EVOTAZ.
Slovenian: Sočasna uporaba zdravila EVOTAZ lahko vpliva na koncentracije dabigatrana.
English: The following side effects may occur when taking EVOTAZ.
Slovenian: Pri jemanju zdravila EVOTAZ se lahko pojavijo naslednji neželeni učinki:
English: Advice on missed doses
Slovenian: Nasvet v primeru izpuščenih odmerkov
English: Voxilaprevir Cmax : ↑342% (↑265%
Slovenian: Voksilaprevir Cmax: ↑342%
English: Concomitant use of St. John's wort with EVOTAZ may be expected to result in significant reduction in plasma levels of cobicistat and atazanavir.
Slovenian: Pri sočasni uporabi šentjanževke in zdravila EVOTAZ lahko pričakujemo pomembno zmanjšanje koncentracije kobicistata in atazanavirja v plazmi.
English: Co-administration of bosentan with cobicistat may lead to decreased cobicistat plasma concentrations.
Slovenian: Pri sočasni uporabi bosentana in kobicistata se koncentracije kobicistata v plazmi lahko zmanjšajo.
English: When co-administering maraviroc and EVOTAZ, patients should receive maraviroc 150 mg twice daily.
Slovenian: Pri sočasni uporabi maraviroka in zdravila EVOTAZ morajo bolniki maravirok jemati v odmerku 150 mg dvakrat na dan. Za podrobnosti glejte povzetek glavnih značilnosti zdravila za maravirok.
English: The use of EVOTAZ is contraindicated in patients with moderate to severe hepatic impairment.
Slovenian: Pri bolnikih z zmerno do hudo okvaro jeter je uporaba zdravila EVOTAZ kontraindicirana.
English: The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2 blockers.
Slovenian: Mehanizem interakcije je manjša topnost atazanavirja pri zvišani pH vrednosti želodčne vsebine zaradi uporabe antagonista histaminskih receptorjev H2.
English: Co-administration with the following medicinal products due to the potential for serious and/or lifethreatening adverse reactions (see section 4.5): colchicine, when used in patients with renal and/or hepatic impairment (antigout) (see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension (see sections 4.4 and 4.5 for co-administration for the treatment of erectile dysfunction), avanafil (PDE5 inhibitors) simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) (see section 4.5) glecaprevir/pibrentasvir fixed dose combination (see section 4.5)
Slovenian: Sočasna uporaba z naslednjimi zdravili zaradi možnega pojava resnih in/ali smrtno nevarnih neželenih učinkov (glejte poglavje 4.5): kolhicin, če se ga uporablja pri bolnikih z okvaro ledvic in/ali jeter (zdravilo za zdravljenje protina) (glejte poglavje 4.5).
English: Concentrations of these antiarrhythmics may be increased when co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se koncentracije teh antiaritmikov lahko povečajo.
English: No clinically relevant differences in cobicistat pharmacokinetics were observed between subjects with moderate impairment and healthy subjects.
Slovenian: Farmakokinetika kobicistata se pri bolnikih z zmerno okvaro jeter ni klinično pomembneje razlikovala od farmakokinetike pri zdravih osebah.
English: carbamazepine, phenobarbital and phenytoin (antiepileptics used to prevent seizures) astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); amiodarone, dronedarone, quinidine, lidocaine (injectable) or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, ergometrine and methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat schizophrenia) medicines containing St. John's wort (Hypericum perforatum, a herbal preparation).
Slovenian: če jemljete katero od naslednjih zdravil: glejte tudi Druga zdravila in zdravilo EVOTAZ rifampicin (antibiotik za zdravljenje tuberkuloze) karbamazepin, fenobarbital in fenitoin (antiepileptiki za preprečevanje epileptičnih napadov) astemizol ali terfenadin (pogosto ju uporabljamo za zdravljenje simptomov alergije, ti zdravili sta lahko na voljo tudi brez recepta); cisaprid (uporabljamo ga za zdravljenje zatekanja želodčne vsebine nazaj v požiralnik ali zgage); pimozid (uporabljamo ga za zdravljenje shizofrenije); amiodaron, dronedaron, kinidin, lidokain (v obliki injekcij) ali bepridil (uporabljamo jih za zdravljenje motenj srčnega ritma); ergotamin, dihidroergotamin, ergonovin, ergometrin in metilergonovin (uporabljamo jih za zdravljenje glavobolov) in alfuzosin (uporabljamo ga za zdravljenje povečane prostate) kvetiapin (uporabljamo ga za zdravljenje shizofrenije, bipolarne motnje in velike depresije); lurasidon (uporabljamo ga za zdravljenje shizofrenije) zdravila, ki vsebujejo šentjanževko (Hypericum perforatum, zdravilo rastlinskega izvora) triazolam in peroralne (ki se jih jemlje skozi usta) oblike midazolama (uporabljamo jih kot pomoč pri težavah s spanjem in/ali za ublažitev tesnobe) simvastatin in lovastatin (uporabljamo ju za zniževanje vrednosti holesterola v krvi) avanafil (uporabljamo ga za zdravljenje erektilne disfunkcije) kolhicin (uporabljamo ga za zdravljenje protina), če imate težave z jetri in/ali ledvicami ticagrelor (uporabljamo ga za preprečevanje nastanka krvnih strdkov) zdravila, ki vsebujejo grazoprevir, vključno s fiksno kombinacijo elbasvir/grazoprevir in fiksno kombinacijo glekaprevir/pibrentasvir (uporabljamo jih za zdravljenje kronične okužbe z virusom hepatitisa C).
English: Increased plasma concentrations of medicinal products that are metabolised by CYP3A (including atazanavir) are observed on co-administration with cobicistat.
Slovenian: Pri sočasni uporabi s kobicistatom so poročali o povečanju plazemskih koncentracij zdravil, ki se presnavljajo s CYP3A (vključno z atazanavirjem).
English: EVOTAZ should not be co-administered with triazolam or orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of EVOTAZ and parenteral midazolam.
Slovenian: triazolam in peroralno uporabljen midazolam (sedativi/hipnotiki) (za opozorilo glede parenteralne uporabe midazolama glejte poglavje 4.5).
English: No teratogenic effects were observed in rats or rabbits at maternally toxic doses.
Slovenian: Pri podganah in kuncih pri odmerkih, toksičnih za matere, niso opazili teratogenih učinkov.
English: Nevirapine 200 mg twice daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Slovenian: Nevirapin 200 mg dvakrat na dan (atazanavir 300 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan)
English: Cobicistat Cobicistat has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Slovenian: Kobicistat Pri bolnikih s hudo okvaro jeter (Child-Pugh C) uporabe kobicistata niso raziskovali.
English: Also see PULMONARY ATERIAL HYPERTENSION in this table for further information regarding co-administration of EVOTAZ with sildenafil.
Slovenian: Za nadaljnje informacije o sočasni uporabi zdravila EVOTAZ in sildenafila glejte tudi PLJUČNA ARTERIJSKA HIPERTENZIJA v tej tabeli.
English: No significant effect on lamivudine and zidovudine concentrations was observed when co-administered with atazanavir.
Slovenian: Pri sočasni uporabi atazanavirja pomembnega vpliva na koncentracije lamivudina in zidovudina niso opazili.
English: Atazanavir and cobicistat are metabolised by the hepatic system.
Slovenian: Atazanavir in kobicistat se presnavljata v jetrih.
English: Cobicistat is 97-98% bound to human plasma proteins and the mean plasma to blood drug concentration ratio was 2.
Slovenian: Vezava kobicistata na serumske beljakovine pri človeku je 97-98-odstotna.
English: It is important that you do not miss any doses of EVOTAZ or your other anti-HIV medicines.
Slovenian: Pomembno je, da zdravilo EVOTAZ ali druga zdravila za zdravljenje okužbe z virusom HIV jemljete redno.
English: EVOTAZ may affect how well your kidneys work.
Slovenian: Zdravilo EVOTAZ lahko vpliva na delovanje ledvic.
English: EVOTAZ should be used with caution in patients with mild hepatic impairment.
Slovenian: Pri bolnikih z blago okvaro jeter je treba zdravilo EVOTAZ uporabljati previdno.
English: Tenofovir alafenamide 10 mg once daily (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Slovenian: Alafenamidtenofovirat 10 mg enkrat na dan (atazanavir 300 mg enkrat na dan s kobicistatom 150 mg enkrat na dan)
English: Some patients have reported dizziness when taking atazanavir or cobicistat, active substances of EVOTAZ.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Nekateri bolniki so pri jemanju atazanavirja ali kobicistata, učinkovin zdravila EVOTAZ, poročali o pojavu omotice.
English: Concentrations of these medicinal products may be increased when co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se koncentracije teh zdravil lahko povečajo.
English: Concentration of fluconazole may be increased if co-administered with cobicistat.
Slovenian: Pri sočasni uporabi kobicistata se koncentracije flukonazola lahko povečajo.
English: Plasma concentrations of drospirenone are increased following administration of drospirenone/ethinyloestradiol with atazanavir/cobicistat.
Slovenian: Pri uporabi drospirenona/etinilestradiola skupaj z atazanavirjem/kobicistatom se povečajo koncentracije drospirenona v plazmi.
English: No dose adjustment is required for telaprevir if co-administered with EVOTAZ.
Slovenian: Odmerka telaprevirja pri sočasni uporabi zdravila EVOTAZ ni treba prilagajati.
English: Rivaroxaban
Slovenian: Rivaroksaban
English: Co-administration with EVOTAZ has the potential to increase warfarin plasma concentrations.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se lahko povečajo koncentracije varfarina v plazmi.
English: Co-administration of EVOTAZ with alfuzosin is contraindicated (see section 4.3)
Slovenian: Sočasna uporaba zdravila EVOTAZ in alfuzosina je kontraindicirana (glejte poglavje 4.3).
English: Co-administration of boceprevir and EVOTAZ is not recommended.
Slovenian: Sočasna uporaba boceprevirja in zdravila EVOTAZ ni priporočljiva.
English: Interaction table
Slovenian: Prikaz interakcij v obliki tabele
English: OPIOIDS
Slovenian: ZDRAVILA
English: The mechanism of interaction is inhibition of CYP3A4 by atazanavir and cobicistat.
Slovenian: Mehanizem interakcije je zaviranje CYP3A4 z atazanavirjem in kobicistatom.
English: Co-administration with EVOTAZ is expected to increase dolutegravir plasma concentrations.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ pričakujemo povečanje koncentracij dolutegravirja v plazmi.
English: ANTI-HCV AGENTS Grazoprevir 200 mg once daily (atazanavir 300 mg / ritonavir 100 mg once daily)
Slovenian: Grazoprevir 200 mg enkrat na dan (atazanavir 300 mg/ritonavir 100 mg enkrat na dan)
English: Co-administration of EVOTAZ with proton pump inhibitors (PPIs) is not recommended due to the decreased solubility of atazanavir as intra-gastric pH increase with PPIs (see section 4.5).
Slovenian: Zaviralci protonske črpalke povečajo pH vrednost želodčne vsebine, topnost atazanavirja pa se pri tem zmanjša (glejte poglavje 4.5).
English: ERGOT DERIVATES
Slovenian: DERIVATI ERGOT ALKALOIDOV
English: Telaprevir AUC ↓20% (↓24% Telaprevir Cmax ↓21% (↓26% Telaprevir Cmin ↓15% (↓25% ↓2%) Atazanavir AUC ↑17% (↓3% Atazanavir Cmax ↓15% (↓27% Atazanavir Cmin ↑85% (↑40%
Slovenian: Telaprevir AUC ↓20% (↓24% Telaprevir Cmax ↓21% (↓26% Telaprevir Cmin ↓15% (↓25%
English: Co-administration of EVOTAZ with medicinal products that are moderate to weak inducers of CYP3A may result in decreased plasma concentration of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir.
Slovenian: Pri sočasni uporabi se lahko koncentracije atazanavirja in/ali kobicistata zmanjšajo, kar lahko privede do izgube terapevtskega učinka in možnega razvoja odpornosti proti atazanavirju.